{"nctId":"NCT00969709","briefTitle":"Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder","startDateStruct":{"date":"2009-09"},"conditions":["Major Depressive Disorder"],"count":724,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Levomilnacipran ER"]},{"label":"2","type":"EXPERIMENTAL","interventionNames":["Drug: Levomilnacipran ER"]},{"label":"3","type":"EXPERIMENTAL","interventionNames":["Drug: Levomilnacipran ER"]},{"label":"4","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Levomilnacipran ER","otherNames":[]},{"name":"Levomilnacipran ER","otherNames":[]},{"name":"Levomilnacipran ER","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men and women, 18-65 years old\n* Currently meet the DSM-IV-TR criteria for Major Depressive Disorder\n* The patient's current depressive episode must be at least 8 weeks in duration\n\nExclusion Criteria:\n\n* Women who are pregnant, women who will be breastfeeding during the study, and women with childbearing potential who are not practicing a reliable method of birth control\n* Patients with a history of meeting DSM-IV-TR criteria for:\n\n  * any manic or hypomanic episode\n  * schizophrenia or any other psychotic disorder\n  * obsessive-compulsive disorder\n* Patients who are considered a suicide risk","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Montgomery-Ã…sberg Depression Rating Scale (MADRS) Total Score","description":"The MADRS was used to assess depressive symptomatology during the past week. Patients are rated on 10 items to assess feelings of sadness, lassitude, pessimism, inner tension, suicidality, reduced sleep or appetite, difficulty concentrating, and lack of interest.\n\nEach item of the 10 items are scored on a 7-point scale. A score of 0 indicates the absence of symptoms,and a score of 6 indicates symptoms of maximum severity. The total MADRS score for this measure ranges from 0 (absence of symptoms) to 60 (maximum severity for all measured symptoms).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.6","spread":"0.97"},{"groupId":"OG001","value":"-14.8","spread":"0.99"},{"groupId":"OG002","value":"-15.6","spread":"1.00"},{"groupId":"OG003","value":"-16.5","spread":"1.02"}]}]}]},{"type":"SECONDARY","title":"Change in Sheehan Disability Scale (SDS) Total Score","description":"The Sheehan Disability Scale (SDS) is a 3-item clinician-rated questionnaire used to evaluate functional impairments in the domains of work, social life/leisure, and family life/home responsibility. All items are rated on an 11-point continuum (0 = no impairment to 10 = most severe) with the total SDS score ranging from 0 (no impairment) to 30 (most severe for all measured symptoms)","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.2","spread":"0.74"},{"groupId":"OG001","value":"-8.6","spread":"0.75"},{"groupId":"OG002","value":"-9.7","spread":"0.77"},{"groupId":"OG003","value":"-9.7","spread":"0.78"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":176},"commonTop":["Headache","Nausea","Dry mouth","Constipation","Heart rate increased"]}}}